Načítá se...
Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus
IMPORTANCE: Cutaneous lupus erythematosus (CLE) can be severe and treatment resistant. B-cell depletion therapy (BCDT) with rituximab is well recognized in organ involvement in systemic lupus erythematosus (SLE), but its efficacy in cutaneous manifestations is less well established. OBJECTIVE: To ev...
Uloženo v:
| Vydáno v: | JAMA Dermatol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Medical Association
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6583321/ https://ncbi.nlm.nih.gov/pubmed/30383114 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2018.3793 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|